Effects of Donepezil on Deficits Associated With Age-Related Decrease of Growth Hormone
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The planned study has two purposes:
1. It is to provide evidence that the administration of a cholinesterase inhibitor will
result in an increase of IGF-I (primary variable) and in an increase of the secretion
growth hormone (secondary variable) that can be maintained throughout the
treatment-period of one year.
2. The study also tests the hypothesis that maintenance of increased blood levels of growth
hormone and IGF-I can stop or delay the age-related changes of body composition
(secondary variables) .